Gene-mutated HIV-1/SIV chimeric viruses as AIDS live attenuated vaccines for potential human use
To develop an AIDS vaccine for human use as well as a suitable animal model for AIDS research, we constructed a series of HIV-1/SIVmac chimeric viruses (SHIVs). We successfully generated a SHIV (designated as NM-3rN) having the HIV-1 env gene, which enabled the evaluation of the efficacy of HIV-1 En...
Gespeichert in:
| Veröffentlicht in: | Leukemia 1999-04, Vol.13, p.42-47 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 47 |
|---|---|
| container_issue | |
| container_start_page | 42 |
| container_title | Leukemia |
| container_volume | 13 |
| creator | HAYAMI, M IGARASHI, T KUWATA, T UI, M HAGA, T AMI, Y SHINOHARA, K HONDA, M |
| description | To develop an AIDS vaccine for human use as well as a suitable animal model for AIDS research, we constructed a series of HIV-1/SIVmac chimeric viruses (SHIVs). We successfully generated a SHIV (designated as NM-3rN) having the HIV-1 env gene, which enabled the evaluation of the efficacy of HIV-1 Env-targeted vaccines in macaque monkeys instead of chimpanzees. Two NM-3rN derivatives (NM-3 and NM-3n) induced long-term anti-virus immunities without manifesting the disease. The monkeys vaccinated with NM-3 or NM-3n became resistant to a challenge inoculation with NM-3rN. Serum from a monkey vaccinated with NM-3 neutralized not only the parental HIV-1 (NL432), but also an antigenically different HIV-1 (MN). In vivo experiments confirmed the heterologous protection against an SHIV having the HIV-1 (MN) env. In addition to specific immunity including neutralizing antibodies and cytotoxic T lymphocyte activity, nonspecific immunity such as natural killer activity is associated with this protection. These data suggest that the live vaccine has the ability to protect individuals against various types of HIVs. These SHIVs should contribute to the development of future anti-HIV-1 live vaccines in humans. |
| doi_str_mv | 10.1038/sj.leu.2401283 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_17252375</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2645697683</sourcerecordid><originalsourceid>FETCH-LOGICAL-c380t-a373142b647695140bcbe67ad9d2375661ae81f6388f2fd842707d71d9f85b883</originalsourceid><addsrcrecordid>eNpd0E1LAzEQBuAgiq3Vq0cJKN62zXeyR6naFgoeqr2u2WyWpuxH3WwK_ntTrQieBmaedxgGgGuMxhhRNfHbcWXDmDCEiaInYIiZFAnnHJ-CIVJKJiIlbAAuvN8idBiKczDAiFBCBRuC95ltbFKHXve2gPPFOsGT1WINzcbVtnMG7l0XvPVQe_iweFzByu0t1H1vm_Ad2WtjXBNB2XZw18Z-73QFN6HWDYzJS3BW6srbq2Mdgbfnp9fpPFm-zBbTh2ViqEJ9oqmkmJFcxAtTjhnKTW6F1EVaECq5EFhbhUtBlSpJWShGJJKFxEVaKp4rRUfg_mfvrms_gvV9VjtvbFXpxrbBZ1gSftgU4e0_uG1D18TbMiIYF6kUikZ1c1Qhr22R7TpX6-4z-_1cBHdHoL3RVdnpxjj_5xQinCL6BZxmer8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2645697683</pqid></control><display><type>article</type><title>Gene-mutated HIV-1/SIV chimeric viruses as AIDS live attenuated vaccines for potential human use</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><source>Nature Journals Online</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>HAYAMI, M ; IGARASHI, T ; KUWATA, T ; UI, M ; HAGA, T ; AMI, Y ; SHINOHARA, K ; HONDA, M</creator><creatorcontrib>HAYAMI, M ; IGARASHI, T ; KUWATA, T ; UI, M ; HAGA, T ; AMI, Y ; SHINOHARA, K ; HONDA, M</creatorcontrib><description>To develop an AIDS vaccine for human use as well as a suitable animal model for AIDS research, we constructed a series of HIV-1/SIVmac chimeric viruses (SHIVs). We successfully generated a SHIV (designated as NM-3rN) having the HIV-1 env gene, which enabled the evaluation of the efficacy of HIV-1 Env-targeted vaccines in macaque monkeys instead of chimpanzees. Two NM-3rN derivatives (NM-3 and NM-3n) induced long-term anti-virus immunities without manifesting the disease. The monkeys vaccinated with NM-3 or NM-3n became resistant to a challenge inoculation with NM-3rN. Serum from a monkey vaccinated with NM-3 neutralized not only the parental HIV-1 (NL432), but also an antigenically different HIV-1 (MN). In vivo experiments confirmed the heterologous protection against an SHIV having the HIV-1 (MN) env. In addition to specific immunity including neutralizing antibodies and cytotoxic T lymphocyte activity, nonspecific immunity such as natural killer activity is associated with this protection. These data suggest that the live vaccine has the ability to protect individuals against various types of HIVs. These SHIVs should contribute to the development of future anti-HIV-1 live vaccines in humans.</description><identifier>ISSN: 0887-6924</identifier><identifier>EISSN: 1476-5551</identifier><identifier>DOI: 10.1038/sj.leu.2401283</identifier><identifier>PMID: 10232364</identifier><identifier>CODEN: LEUKED</identifier><language>eng</language><publisher>London: Nature Publishing</publisher><subject>Acquired immune deficiency syndrome ; AIDS ; AIDS Vaccines - toxicity ; Animal models ; Animals ; Antibodies ; Antibodies, Viral - biosynthesis ; Antiviral agents ; Biological and medical sciences ; Cytotoxicity ; Env gene ; Experimental and animal immunopathology. Animal models ; Female ; Gene Products, env - immunology ; Gene Products, gag - immunology ; Gene Products, nef - immunology ; Gene Products, vpr - immunology ; Genes, env ; Genes, gag ; Genes, nef ; Genes, vpr ; HIV ; HIV Antibodies - biosynthesis ; HIV-1 - genetics ; HIV-1 - immunology ; Human immunodeficiency virus ; Humans ; Immunity ; Immunopathology ; Inoculation ; Killer Cells, Natural - immunology ; Lymphocytes ; Lymphocytes T ; Macaca fascicularis ; Male ; Medical sciences ; Monkeys ; nef Gene Products, Human Immunodeficiency Virus ; Neutralization Tests ; Public health ; Reassortant Viruses - genetics ; Reassortant Viruses - immunology ; Simian Immunodeficiency Virus - genetics ; Simian Immunodeficiency Virus - immunology ; T-Lymphocytes, Cytotoxic - immunology ; Vaccination ; Vaccines ; Vaccines, Attenuated ; Viremia - etiology ; Viruses ; vpr Gene Products, Human Immunodeficiency Virus</subject><ispartof>Leukemia, 1999-04, Vol.13, p.42-47</ispartof><rights>1999 INIST-CNRS</rights><rights>Macmillan Publishers Limited 1999.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c380t-a373142b647695140bcbe67ad9d2375661ae81f6388f2fd842707d71d9f85b883</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>309,310,314,777,781,786,787,23911,23912,25121,27905,27906</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1802530$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10232364$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>HAYAMI, M</creatorcontrib><creatorcontrib>IGARASHI, T</creatorcontrib><creatorcontrib>KUWATA, T</creatorcontrib><creatorcontrib>UI, M</creatorcontrib><creatorcontrib>HAGA, T</creatorcontrib><creatorcontrib>AMI, Y</creatorcontrib><creatorcontrib>SHINOHARA, K</creatorcontrib><creatorcontrib>HONDA, M</creatorcontrib><title>Gene-mutated HIV-1/SIV chimeric viruses as AIDS live attenuated vaccines for potential human use</title><title>Leukemia</title><addtitle>Leukemia</addtitle><description>To develop an AIDS vaccine for human use as well as a suitable animal model for AIDS research, we constructed a series of HIV-1/SIVmac chimeric viruses (SHIVs). We successfully generated a SHIV (designated as NM-3rN) having the HIV-1 env gene, which enabled the evaluation of the efficacy of HIV-1 Env-targeted vaccines in macaque monkeys instead of chimpanzees. Two NM-3rN derivatives (NM-3 and NM-3n) induced long-term anti-virus immunities without manifesting the disease. The monkeys vaccinated with NM-3 or NM-3n became resistant to a challenge inoculation with NM-3rN. Serum from a monkey vaccinated with NM-3 neutralized not only the parental HIV-1 (NL432), but also an antigenically different HIV-1 (MN). In vivo experiments confirmed the heterologous protection against an SHIV having the HIV-1 (MN) env. In addition to specific immunity including neutralizing antibodies and cytotoxic T lymphocyte activity, nonspecific immunity such as natural killer activity is associated with this protection. These data suggest that the live vaccine has the ability to protect individuals against various types of HIVs. These SHIVs should contribute to the development of future anti-HIV-1 live vaccines in humans.</description><subject>Acquired immune deficiency syndrome</subject><subject>AIDS</subject><subject>AIDS Vaccines - toxicity</subject><subject>Animal models</subject><subject>Animals</subject><subject>Antibodies</subject><subject>Antibodies, Viral - biosynthesis</subject><subject>Antiviral agents</subject><subject>Biological and medical sciences</subject><subject>Cytotoxicity</subject><subject>Env gene</subject><subject>Experimental and animal immunopathology. Animal models</subject><subject>Female</subject><subject>Gene Products, env - immunology</subject><subject>Gene Products, gag - immunology</subject><subject>Gene Products, nef - immunology</subject><subject>Gene Products, vpr - immunology</subject><subject>Genes, env</subject><subject>Genes, gag</subject><subject>Genes, nef</subject><subject>Genes, vpr</subject><subject>HIV</subject><subject>HIV Antibodies - biosynthesis</subject><subject>HIV-1 - genetics</subject><subject>HIV-1 - immunology</subject><subject>Human immunodeficiency virus</subject><subject>Humans</subject><subject>Immunity</subject><subject>Immunopathology</subject><subject>Inoculation</subject><subject>Killer Cells, Natural - immunology</subject><subject>Lymphocytes</subject><subject>Lymphocytes T</subject><subject>Macaca fascicularis</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Monkeys</subject><subject>nef Gene Products, Human Immunodeficiency Virus</subject><subject>Neutralization Tests</subject><subject>Public health</subject><subject>Reassortant Viruses - genetics</subject><subject>Reassortant Viruses - immunology</subject><subject>Simian Immunodeficiency Virus - genetics</subject><subject>Simian Immunodeficiency Virus - immunology</subject><subject>T-Lymphocytes, Cytotoxic - immunology</subject><subject>Vaccination</subject><subject>Vaccines</subject><subject>Vaccines, Attenuated</subject><subject>Viremia - etiology</subject><subject>Viruses</subject><subject>vpr Gene Products, Human Immunodeficiency Virus</subject><issn>0887-6924</issn><issn>1476-5551</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1999</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpd0E1LAzEQBuAgiq3Vq0cJKN62zXeyR6naFgoeqr2u2WyWpuxH3WwK_ntTrQieBmaedxgGgGuMxhhRNfHbcWXDmDCEiaInYIiZFAnnHJ-CIVJKJiIlbAAuvN8idBiKczDAiFBCBRuC95ltbFKHXve2gPPFOsGT1WINzcbVtnMG7l0XvPVQe_iweFzByu0t1H1vm_Ad2WtjXBNB2XZw18Z-73QFN6HWDYzJS3BW6srbq2Mdgbfnp9fpPFm-zBbTh2ViqEJ9oqmkmJFcxAtTjhnKTW6F1EVaECq5EFhbhUtBlSpJWShGJJKFxEVaKp4rRUfg_mfvrms_gvV9VjtvbFXpxrbBZ1gSftgU4e0_uG1D18TbMiIYF6kUikZ1c1Qhr22R7TpX6-4z-_1cBHdHoL3RVdnpxjj_5xQinCL6BZxmer8</recordid><startdate>19990401</startdate><enddate>19990401</enddate><creator>HAYAMI, M</creator><creator>IGARASHI, T</creator><creator>KUWATA, T</creator><creator>UI, M</creator><creator>HAGA, T</creator><creator>AMI, Y</creator><creator>SHINOHARA, K</creator><creator>HONDA, M</creator><general>Nature Publishing</general><general>Nature Publishing Group</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7QL</scope><scope>7T5</scope><scope>7T7</scope><scope>7TM</scope><scope>7TO</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>NAPCQ</scope><scope>P64</scope><scope>7QO</scope></search><sort><creationdate>19990401</creationdate><title>Gene-mutated HIV-1/SIV chimeric viruses as AIDS live attenuated vaccines for potential human use</title><author>HAYAMI, M ; IGARASHI, T ; KUWATA, T ; UI, M ; HAGA, T ; AMI, Y ; SHINOHARA, K ; HONDA, M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c380t-a373142b647695140bcbe67ad9d2375661ae81f6388f2fd842707d71d9f85b883</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1999</creationdate><topic>Acquired immune deficiency syndrome</topic><topic>AIDS</topic><topic>AIDS Vaccines - toxicity</topic><topic>Animal models</topic><topic>Animals</topic><topic>Antibodies</topic><topic>Antibodies, Viral - biosynthesis</topic><topic>Antiviral agents</topic><topic>Biological and medical sciences</topic><topic>Cytotoxicity</topic><topic>Env gene</topic><topic>Experimental and animal immunopathology. Animal models</topic><topic>Female</topic><topic>Gene Products, env - immunology</topic><topic>Gene Products, gag - immunology</topic><topic>Gene Products, nef - immunology</topic><topic>Gene Products, vpr - immunology</topic><topic>Genes, env</topic><topic>Genes, gag</topic><topic>Genes, nef</topic><topic>Genes, vpr</topic><topic>HIV</topic><topic>HIV Antibodies - biosynthesis</topic><topic>HIV-1 - genetics</topic><topic>HIV-1 - immunology</topic><topic>Human immunodeficiency virus</topic><topic>Humans</topic><topic>Immunity</topic><topic>Immunopathology</topic><topic>Inoculation</topic><topic>Killer Cells, Natural - immunology</topic><topic>Lymphocytes</topic><topic>Lymphocytes T</topic><topic>Macaca fascicularis</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Monkeys</topic><topic>nef Gene Products, Human Immunodeficiency Virus</topic><topic>Neutralization Tests</topic><topic>Public health</topic><topic>Reassortant Viruses - genetics</topic><topic>Reassortant Viruses - immunology</topic><topic>Simian Immunodeficiency Virus - genetics</topic><topic>Simian Immunodeficiency Virus - immunology</topic><topic>T-Lymphocytes, Cytotoxic - immunology</topic><topic>Vaccination</topic><topic>Vaccines</topic><topic>Vaccines, Attenuated</topic><topic>Viremia - etiology</topic><topic>Viruses</topic><topic>vpr Gene Products, Human Immunodeficiency Virus</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>HAYAMI, M</creatorcontrib><creatorcontrib>IGARASHI, T</creatorcontrib><creatorcontrib>KUWATA, T</creatorcontrib><creatorcontrib>UI, M</creatorcontrib><creatorcontrib>HAGA, T</creatorcontrib><creatorcontrib>AMI, Y</creatorcontrib><creatorcontrib>SHINOHARA, K</creatorcontrib><creatorcontrib>HONDA, M</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Immunology Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Biotechnology Research Abstracts</collection><jtitle>Leukemia</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>HAYAMI, M</au><au>IGARASHI, T</au><au>KUWATA, T</au><au>UI, M</au><au>HAGA, T</au><au>AMI, Y</au><au>SHINOHARA, K</au><au>HONDA, M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Gene-mutated HIV-1/SIV chimeric viruses as AIDS live attenuated vaccines for potential human use</atitle><jtitle>Leukemia</jtitle><addtitle>Leukemia</addtitle><date>1999-04-01</date><risdate>1999</risdate><volume>13</volume><spage>42</spage><epage>47</epage><pages>42-47</pages><issn>0887-6924</issn><eissn>1476-5551</eissn><coden>LEUKED</coden><abstract>To develop an AIDS vaccine for human use as well as a suitable animal model for AIDS research, we constructed a series of HIV-1/SIVmac chimeric viruses (SHIVs). We successfully generated a SHIV (designated as NM-3rN) having the HIV-1 env gene, which enabled the evaluation of the efficacy of HIV-1 Env-targeted vaccines in macaque monkeys instead of chimpanzees. Two NM-3rN derivatives (NM-3 and NM-3n) induced long-term anti-virus immunities without manifesting the disease. The monkeys vaccinated with NM-3 or NM-3n became resistant to a challenge inoculation with NM-3rN. Serum from a monkey vaccinated with NM-3 neutralized not only the parental HIV-1 (NL432), but also an antigenically different HIV-1 (MN). In vivo experiments confirmed the heterologous protection against an SHIV having the HIV-1 (MN) env. In addition to specific immunity including neutralizing antibodies and cytotoxic T lymphocyte activity, nonspecific immunity such as natural killer activity is associated with this protection. These data suggest that the live vaccine has the ability to protect individuals against various types of HIVs. These SHIVs should contribute to the development of future anti-HIV-1 live vaccines in humans.</abstract><cop>London</cop><pub>Nature Publishing</pub><pmid>10232364</pmid><doi>10.1038/sj.leu.2401283</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0887-6924 |
| ispartof | Leukemia, 1999-04, Vol.13, p.42-47 |
| issn | 0887-6924 1476-5551 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_17252375 |
| source | MEDLINE; Springer Nature - Complete Springer Journals; Nature Journals Online; EZB-FREE-00999 freely available EZB journals |
| subjects | Acquired immune deficiency syndrome AIDS AIDS Vaccines - toxicity Animal models Animals Antibodies Antibodies, Viral - biosynthesis Antiviral agents Biological and medical sciences Cytotoxicity Env gene Experimental and animal immunopathology. Animal models Female Gene Products, env - immunology Gene Products, gag - immunology Gene Products, nef - immunology Gene Products, vpr - immunology Genes, env Genes, gag Genes, nef Genes, vpr HIV HIV Antibodies - biosynthesis HIV-1 - genetics HIV-1 - immunology Human immunodeficiency virus Humans Immunity Immunopathology Inoculation Killer Cells, Natural - immunology Lymphocytes Lymphocytes T Macaca fascicularis Male Medical sciences Monkeys nef Gene Products, Human Immunodeficiency Virus Neutralization Tests Public health Reassortant Viruses - genetics Reassortant Viruses - immunology Simian Immunodeficiency Virus - genetics Simian Immunodeficiency Virus - immunology T-Lymphocytes, Cytotoxic - immunology Vaccination Vaccines Vaccines, Attenuated Viremia - etiology Viruses vpr Gene Products, Human Immunodeficiency Virus |
| title | Gene-mutated HIV-1/SIV chimeric viruses as AIDS live attenuated vaccines for potential human use |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T01%3A24%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Gene-mutated%20HIV-1/SIV%20chimeric%20viruses%20as%20AIDS%20live%20attenuated%20vaccines%20for%20potential%20human%20use&rft.jtitle=Leukemia&rft.au=HAYAMI,%20M&rft.date=1999-04-01&rft.volume=13&rft.spage=42&rft.epage=47&rft.pages=42-47&rft.issn=0887-6924&rft.eissn=1476-5551&rft.coden=LEUKED&rft_id=info:doi/10.1038/sj.leu.2401283&rft_dat=%3Cproquest_pubme%3E2645697683%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2645697683&rft_id=info:pmid/10232364&rfr_iscdi=true |